Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that diagnosing and treating Interstitial Pneumonia with Autoimmune Features (IPAF) is challenging, needs a multidisciplinary approach, and further research for better diagnostic criteria and treatments. It also emphasizes regular checks for Connective Tissue Disease symptoms in all patients with Interstitial Lung Disease.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.

Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.

Nilotinib can cause keratosis pilaris, a skin condition.

Dupilumab can both cause and treat alopecia areata, with many patients experiencing hair regrowth.

Systemic corticosteroids might help treat hair loss caused by alemtuzumab in MS patients.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.

JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Early and aggressive treatment with individualized care plans is crucial for managing pediatric systemic lupus erythematosus.

Tofacitinib helped a man with alopecia totalis regrow all his hair.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.

PPAR-γ agonists like pioglitazone may help manage lichen planopilaris but don't fully reverse scarring.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Dupilumab can both trigger and treat alopecia areata, often leading to hair regrowth.

Dormant melanoma cells in mice interact minimally with memory T cells due to a suppressive tumor environment.